Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.990 -0.010 (-0.17%)

Official Closing Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,319,083
Open	6.050
Bid (Size)	5.500 (100)
Ask (Size)	6.200 (5,000)
Prev. Close	6.000
Today's Range	5.920 - 6.120
52wk Range	3.530 - 8.590
Shares Outstanding	93,500,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

July 02, 2026

Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories

From Myriad Genetics, Inc.

Via GlobeNewswire

July 01, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Performance

YTD	-2.4%	-2.4%
1 Month	+39.0%	+39.0%
3 Month	+26.1%	+26.1%
6 Month	-2.4%	-2.4%
1 Year	+6.4%	+6.4%

More News

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

June 29, 2026

Via StockStory

Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS ↗

May 05, 2026

Via Chartmill

Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today

June 24, 2026

Via StockStory

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

June 23, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds

June 05, 2026

Via StockStory

3 High-Flying Stocks We’re Skeptical Of

June 04, 2026

Via StockStory

Myriad Genetics Names Raj Jampa as New Chief Technology Officer

June 02, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

May 27, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

May 26, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

1 Unprofitable Stock to Consider Right Now and 2 We Turn Down

May 22, 2026

Via StockStory

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

May 15, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 12, 2026

Via StockStory

3 of Wall Street’s Favorite Stocks with Open Questions

May 12, 2026

Via StockStory

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

May 07, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins

May 06, 2026

Via StockStory

Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%

May 05, 2026

Via StockStory

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

May 05, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect

May 03, 2026

Via StockStory

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

April 30, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

April 28, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

3 Small-Cap Stocks We Think Twice About

April 24, 2026

Via StockStory

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

April 16, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

April 14, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?

Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.

What exchange does Myriad Genetics, Inc. - Common Stock trade on?

Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?

The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market

What is the current price of Myriad Genetics, Inc. - Common Stock?

The current price of Myriad Genetics, Inc. - Common Stock is 5.990

When was Myriad Genetics, Inc. - Common Stock last traded?

The last trade of Myriad Genetics, Inc. - Common Stock was at 07/02/26 04:00 PM ET

What is the market capitalization of Myriad Genetics, Inc. - Common Stock?

The market capitalization of Myriad Genetics, Inc. - Common Stock is 560.07M

How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?

Myriad Genetics, Inc. - Common Stock has 560M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.